P
Paul Taylor
Researcher at University of Manchester
Publications - 46
Citations - 2813
Paul Taylor is an academic researcher from University of Manchester. The author has contributed to research in topics: Stone duality & General topology. The author has an hindex of 16, co-authored 41 publications receiving 2665 citations. Previous affiliations of Paul Taylor include Imperial College London.
Papers
More filters
Book
Proofs and types
TL;DR: In this paper, the Curry-Howard isomorphism and the normalisation theorem of a natural deduction system T coherence spaces have been studied in the context of linear logic and linear logic semantics.
Journal ArticleDOI
High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy
Per Eystein Lønning,Paul Taylor,Gun Anker,Julie Iddon,Liv Wie,Linn-Marie Jørgensen,Olav Mella,Anthony Howell +7 more
TL;DR: The results reveal estrogens administered in high doses may have antitumor effects in breast cancer patients heavily pretreated with endocrine therapy, and represents a valuable alternative to chemotherapy in selected patients.
Book
Practical foundations of mathematics
TL;DR: In this paper, first order reasoning is used to reason about algebra with dependent types, and the quantifiers are used to quantify the quantifier of a given algebraic structure. But the quantification of dependent types is not considered in this paper.
Journal ArticleDOI
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.
Giorgio V. Scagliotti,Rabab Gaafar,Anna K. Nowak,Takashi Nakano,Jan P. van Meerbeeck,Sanjay Popat,Sanjay Popat,Nicholas J. Vogelzang,Federica Grosso,Rasha Aboelhassan,Marko Jakopović,Giovanni Luca Ceresoli,Paul Taylor,Francisco Orlandi,Dean A. Fennell,Silvia Novello,Arnaud Scherpereel,Kozo Kuribayashi,Susana Cedres,Jens Benn Sørensen,Nick Pavlakis,Martin Reck,Derek Velema,Ute von Wangenheim,MI-Young Kim,José Barrueco,Anne S. Tsao +26 more
TL;DR: The primary progression-free survival endpoint of the phase 3 part of the LUME-Meso was not met and phase 2 findings were not confirmed, and no unexpected safety findings were reported.
Journal ArticleDOI
Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: Results of an international expanded access program
Paul Taylor,B. Castagneto,Graham Dark,M. Marangolo,Giorgio V. Scagliotti,Rob J. van Klaveren,Roberto Labianca,Monika Serke,Wolfgang Schuette,Jan P. van Meerbeeck,David F. Heigener,Yushan Liu,S. Adachi,J. Blatter,Joachim von Pawel +14 more
TL;DR: In the present expanded access program, single-agent pemetrexed demonstrated promising activity in MPM in both chemonaïve and pretreated patients, with TTPD of 6.0 and 4.9 months, respectively, 1-year survival ≥54.7%, and mild hematologic toxicity.